However, their in vivo actions are uncertain, and their protective efficacy is proven only in brief cerebral isch emia paradigms. Here we examine their mechanism of action in vitro and duration of efficacy in vivo. Electro physiological studies were made in CAl neurons in rat hippocampal slices. When superfused with BAPTA-AM (30-50 fLM), CAl somatic field potential recordings showed attenuation of the popUlation spike amplitude, and intracellular recordings showed reduced excitatory postsynaptic potentials, indicating inhibition of excitatory synaptic transmission. Also, Caz+ -dependent accommo dation and post-spike-train hyperpolarizations were re duced, indicating Caz + chelation hear the internal cell membrane surface. To determine whether Ca 2 + chelators
In central neurons, an excessive or sustained rise in the concentration of free cytoplasmic Ca2 + ions ([Ca 2 +h) may promote rapid neurodegeneration both in vitro and in vivo (for reviews, see Choi, 1988; Siesjo and Bengtsson, 1989; Farooqui and reduce the size of cerebral infarction rather than simply delaying its evolution, we studied the effects of BAPTA AM treatment on infarction size 24 h after permanent middle cerebral artery occlusion. Fischer rats (n = 8 per group) were pretreated with saline, BAPT A-AM (20 mgt kg), or MK-801 (0.5 mg/kg). Infarction volumes in ani mals treated with BAPTA-AM were reduced by 50.5% compared with controls (p = 0.018), whereas animals treated with MK-801 experienced a statistically insignifi cant infarct volume reduction (26%; p = 0.27). These data show a persistence of neuroprotection by the Ca 2 + chelator at 24 h and indicate that it may act by attenuating synaptic transmission and subplasma membrane Ca 2 + excess. Key Words: 1,2-Bis-(2-aminophenoxy)ethane N,N,N' ,N'-tetraacetic acid acetoxymethy1 ester (BAPTA-AM)-Calcium-Calcium chelators-Cerebral ischemia-Neurotoxicity-Synaptic transmission. Horrocks, 1991) . Although the molecular mecha nisms by which Ca 2 + ions trigger neuronal death are uncertain, certain processes leading to intracel lular Ca 2 + excess have been described. For exam ple, according to the excitotoxicity hypothesis, cel lular Ca 2 + overload during neuronal hypoxial ischemia can occur when neuronal glutamate receptors are overstimulated by excessive excitato ry synaptic activity (Rothman, 1983 (Rothman, , 1984 Rothman and Olney, 1986) . The activation of ionotropic glu tamate receptors produces Ca 2 + influx via ion channels, whereas other increases in [Ca 2 +]i may be triggered by metabotropic glutamate receptors (Courtney et aI. , 1990; Opitz and Reymann, 1991) , by a depolarization-induced activation of voltage gated Ca2 + channels and, possibly, by Ca2 +induced Ca 2 + release from intracellular stores (Miller, 1992) . Since an excitotoxin andlor depolar-ization-induced rise in [Ca 2 +] i is thought to be cen tral to the process of hypoxic/ischemic neurodegen eration, numerous pharmacological agents that block Ca 2 + channels or glutamate receptors have been employed to lessen neuronal damage in cere bral ischemia (e.g., Park et aI. , 1988b; Uematsu et aI., 1989; Sheardown et aI., 1990; Siesjo, 1992b) . However, since there exist multiple pathways by which deleterious [Ca 2 +t increases can occur in the neuronal cytoplasm, strategies employing single, receptor-specific, Ca2 + blockers may fail to pro duce the desired neuroprotective effect (Vibul sresth et aI. , 1987; Koh and Choi, 1991; Nellgard and Wieloch, 1992) .
Recently we reported the first successful treat ment of neuronal ischemic injury in vivo by cell permeant Ca2 + chelators derived from 1,2 bis-(2aminophenoxy) ethane-N,N,N' ,N' -tetraacetic acid (BAPT A) acetoxymethyl ester (AM) (Tymianski et aI., 1993b,c) . BAPTA-AM is a lipophilic compound capable of crossing cell membranes but does not bind Ca 2 + ions and does not alter extracellular Ca 2 + concentrations. However, inside the cell non specific esterases cleave the AM moiety, thereby forming the ionized Ca 2 + binding compound BAPTA that remains trapped within the cell ( Fig. 1 ) (Tsien, 1980 (Tsien, , 1981 . Low concentrations of cell permeant chelator (in the micromolar range) are sufficient to have a profound effect on intracellular [Ca2+]i dynamics (Zhou and Neher, 1993) . Thus, the drug can be administered systemically at con centrations that would have no effect on extracel lular [Ca 2 +] (which is in the millimolar range) but suffice to affect intracellular Ca2+ ions because of their very low intracellular concentration (about 100 nM). Through their chelating action, BAPT A and .;AM Esterified to Ca" , chelating sites
its derivatives are thought to act directly on intra cellular Ca 2 + elevations, rather than by blocking specific neuronal receptors (such a the N-methyl-o aspartate receptor), which, when activated, are ca pable of raising the [Ca 2 +]i' The chelators may in crease the resilience of neurons to neurotoxic in sults by increasing their capacity to buffer excessive Ca2+ loads (Tymianski et aI., 1993b) or by modifying the diffusion of intracellular Ca2+ ions (Zhou and Neher, 1993) . These compounds provide a powerful alternative strategy for the treatment of cerebral ischemia by reducing the toxic effects of Ca 2 + ions regardless of the source of Ca2+ influx. We recently reported that Ca 2 + chelators can ac cumulate inside neurons when injected intrave nously in rats, and animals treated with these agents sustain smaller cortical infarctions after 4 h of focal cortical ischemia (Tymianski et aI., 1993b) . How ever, due to the novelty of this therapeutic ap proach, little is known about the chelators' mecha nism of action and the duration of their neuropro tective effect. For instance, it is unknown whether Ca 2 + chelators simply delay the onset of neurode generation or whether they produce a permanent reduction inJocal infarction size. Also, although the chelators are thought to act primarily by restricting cytoplasmic [Ca 2 +]i elevations, these compounds have been shown to attenuate neurotransmission in a number of in vitro preparations (Adler et aI., 1991; Niesen et aI. , 1991; Robitaille and Charlton, 1992) . Therefore, they may protect neurons during a stroke by attenuating excitatory neurotransmission (and thereby decreasing excitotoxicity) as well as by buffering excessive Ca 2 + increases.
The goals in this study, therefore, were to study the effects of the cell-permeant Ca 2 + chelator 
BAPTA BAPT A-AM on excitatory neurotransmission in central mammalian neurons and to examine wheth er its neuroprotective effects in focal neocortical ischemia persist beyond the previously reported 4 h.
MATERIALS AND METHODS

Drug preparation
For the electrophysiology experiments, BAPTA-AM was first dissolved in dimethyl sulfoxide (DMSO) and then diluted to its final concentration (50 fLM) in the ex tracellular recording solution. In some experiments, 2-hy droxypropyl-l3-cyclodextrin (0.2% wt/vol; Research Bio chemicals International) and neostigmine (10-15 fLM) were used to minimize deesterification of the chelator in the extracellular solution and to maximize its penetration into neurons in the brain slice.
For the animal experiments, desiccated BAPTA-AM (lot 2221-5, Molecular Probes Inc.) was dissolved in dry DMSO at 10 mg/ml and maintained at -70°C until used. Since the reconstituted chelator appears to become inef fective when maintained in plastic containers (M. Tymi anski, personal observation), this agent, which is light sensitive, was maintained in opacified glass vials at all times. Prior to its use, the vials' contents were warmed to room temperature, then transferred to a I-ml glass sy ringe connected to a 30-cm-Iong, 20-gauge metal needle and mounted on an infusion pump. The needle was then connected to the rat's femoral vein via an indwelling poly ethylene catheter, which was cut to the shortest possible length (about 2 cm) to minimize contact between the re constituted chelator and the plastic tubing. The syringe and all tubings were covered with aluminum foil through out the infusion to minimize the drug's exposure to light. Powdered MK-801 (dizocilpine maleate) was reconsti tuted first in ethanol (5 mg/ml, wt/vol) and then diluted 20-fold in saline to 0.25 mg of MK-801lml of fluid.
Recordings of somatic field potentials and intracellular responses
Four hundred-micrometer transverse brain slices were obtained from mature male Wistar rats weighing 200-300 g by standard methods and maintained at room tempera ture for at least 1 h prior to the initiation of recordings. They were perfused with artificial cerebrospinal fluid (ACSF) containing (mM) 125 NaCI, 2.5 KCl, 1.25 NaHzP04; 2 MgClz; 2 CaCI; 25 NaHC03, and 10 glucose, pH 7.4, aerated with 5% CO 2 /95% O 2 , The brain slices were transferred to a submersion-type chamber perfused with ACSF and maintained at 34.5 ± OSC. Recordings were obtained from hippocampal CAl neurons. Field potentials and intracellularly recorded synaptic responses were evoked by stimulating the Schaf fer collaterals using a bipolar tungsten electrode. Stimu lation intensities were chosen to evoke control responses at 30-50% of maximum. Brief hypoxia was induced by switching from 95% O 2 /5% CO 2 to 95% N 2 /5% CO 2 in both the perfusate container and the recording chamber (Zhang and Krnjevic, 1993) . For intracellular recordings, sharp microelectrodes [l 00-150 mn (Niesen et aI., 1991) ] contained 3 M K-acetate. Neurons were impaled for at least 10 min prior to data acquisition. Afterhyperpolariza tion (AHP) areas ( Fig. 3G) were obtained by integrating from the initial hyperpolarization following spike dis charge evoked by a depolarizing current command (900 pA, 120 ms), to the end of a 4-s episode.
Animal preparation and in vivo experimental protocol
The animal study was performed and analyzed in a blinded, randomized fashion and included three groups comprising animals treated with either MK-801, BAPTA AM, or the drug vehicles along (groups A, B, and C). Owing to the novelty of using BAPTA-AM as a neuro protectant, detailed pharmacokinetic data on this chelator are lacking. To date, the sole demonstration of the agent's arrival into neurons in vivo was at 4 h following the ini tiation of a slow (40-to 50-min) drug infusion (Tymianski et aI., 1993b) . Therefore, it was elected to reuse this pre treatment paradigm in the present experiment. In con trast, several investigators have successfully demon strated a neuroprotective effect of MK-801 in focal cere bral ischemia by infusing the drug a short period (30 min) prior to ischemia onset (e.g., Ozyurt et aI., 1988; Park et aI., 1988a) . Therefore, the present experiments were per formed under the assumption that the two agents differed in the time required for optimal effectiveness, and thus two separate infusions were performed: BAPTA-AM (or vehicle) was administered 4 h prior to ischemia onset, whereas MK-801 (or vehicle) was administered 30 min prior to the induction of ischemia ( Fig. 4A ).
Male Fischer 344 rats (240 ± 34 g) were anesthetized with 1-1.5% halothane and 70/30% nitrous oxide/oxygen, and ventilated by a face mask. Arterial and venous access were obtained through polyethylene catheters inserted into the femoral vessels. The animals were randomly al located to one of the three experimental groups following the induction of the anesthetic and insertion of femoral lines. BAPTA-AM in DMSO (dose of 20 mg/kg BAPTA AM in 2 mllkg DMSO) or DMSO alone was prepared and infused as above over a 45-min period, following which the animals were awakened and returned to their cages. After a further 2.5 h, the animals were reanesthetized, endotracheally intubated, and ventilated. Mean arterial pressures, rectal temperatures, and arterial pH and blood gases were maintained and monitored. Thirty minutes prior to the induction of cerebral ischemia, animals from group A were infused intravenously with MK-80l (0.5 mg/kg) in 5% ethanoll95% saline, whereas groups B and C received only the 5% ethanoll95% saline vehicle. Thus, prior to the induction of cerebral ischemia, group A was pretreated with MK-80l , group B with BAPTA-AM, and group C with neither agent.
Focal cortical ischemia was induced as per Brint et al. (1988) by tandem occlusion of the left common carotid artery (CCA) and ipsilateral distal middle cerebral artery (MCA) (CCAO + MCAO). Briefly, the left CCA was dissected free through a midline cervical incision and per manently ligated with a 4-0 silk ligature. The left MCA was exposed through a 2-mm burr hole drilled 2-3 mm rostral to the fusion of the zygomatic arch with the squamosal bone, occluded with a bipolar electrocautery tip, and then permanently divided with a microscissors. The site of the occlusion was just superior to the rhinal fissure. Physiological monitoring was carried out from the time of intubation until at least 60 min following MCAO. Then the rats were awakened and replaced in their cage. Upon awakening, the rats were allowed to extubate them selves by moving away from the endotracheal tube, which was anchored to the anesthetic apparatus. The time interval between cessation of the anesthetic and self extubation was noted. The 24-h ischemia paradigm pre cluded close monitoring of physiological parameters throughout the entire ischemic period in the awake rat. However, the rats were observed intermittently through out this time to ensure that no gross behavioral or phys iological abnormalities occurred (e.g., seizures or respi ratory compromise). Since high doses of MK-801 produce obtundation (Rod and Auer, 1992) , we used a dose of 0.5 mg/kg, as this was shown to protect against focal isch emic damage in the rat (Park et aI., 1988a) while still allowing the animal to awaken following termination of the anesthetic.
Twenty-four hours following the onset of cortical isch emia, the neurologic status of each animal was evaluated using the grading system of Bederson et al. (1986) (Grade 0, normal behavior; Grade 1, forelimb flexion; Grade 2, decreased resistance to lateral push; Grade 3, same as grade 2, with circling). This grading was originally devel oped for the focal ischemia model of Tamura et al. (1981) , and its validity to the ischemia model of Brint et at. (1988) is unknown. However, the authors are unaware of a re liable neurological grading system for the latter model.
After neurological assessment, each animal was rean esthetized with halothane. The descending aorta was can nulated and heparinized saline was infused to clear the vasculature of blood. Perfusion fixation was achieved with 10% formalin in saline infused at 80 mm Hg. The heads were placed in formalin for 24 h before the brains were removed and maintained in the formalin for a further 48 h. The brains were then mounted in paraffin blocks and processed for histology. They were serially sectioned (7 J.Lm thick) and stained with hematoxylin/eosin. Each sec tion was examined by light microscopy by a blinded in vestigator (M.C.W.), and again by a second blinded in vestigator (M.P.C.), solely to check for interobserver variability in the assessment of cerebral infarction areas (this was less than 5% per area studied).
The extent of ischemic damage in each brain was eval uated by integrating the volume of cortical infarction from the histopathological defects seen in eight standard coro nal brain sections. The evaluation was unaffected by con founding factors such as brain swelling (Gotoh et aI., 1985; Hatashita and Hoff, 1990) , because the histopatho logical defects were evaluated with the aid of standard templates as per Osborne et al. (1987) . Therefore, the result directly reflected neuronal tissue damage.
Statistical analysis
Statistical analyses were performed using analysis of variance (ANOV A) with posthoc multiple comparisons using the Bonferoni correction procedure to determine significant differences between individual group means (see Altman, 1991) . Student's t test was employed when ever only two group means were compared. All means are provided with their standard deviations.
RESULTS
BAPT A-AM attenuates excitatory neurotransmission in brain slices
Recently we showed that neuroprotection by high-affinity Ca 2 + chelators was associated with an attenuation of intracellular Ca 2 + increases as de- Vol. 14, No. 6, 1994 tected with the fluorescent Ca 2 + indicator fl;lra-2 (Tymianski et aI., 1993b) . However, this associa tion is not absolute, because in further experiments, neuroprotection could also be achieved in vitro by chelators that have lesser effects on measurable [Ca 2 +Ji increases (Tymianski et aI. , 1994) . Thus, an action in addition to the bulk buffering of cytoplas mic Ca2 + might be contributing to the neuroprotec tive mechanism of these agents.
One such mechanism may be the chelator's ef fects on synaptic transmission. Calcium entry into presynaptic terminals triggers neurotransmitter re lease (Augustine et aI. , 1985; Smith and Augustine, 1988) and is attenuated by intracellular Ca 2 + chela tion in numerous experimental preparations (Adler et a1. , 1991; Augustine et aI., 1991; Niesen et aI. , 1991; Robitaille and Chariton, 1992) . Since synaptic overactivity is thought to mediate hypoxic ischemic brain damage by causing excessive excit atory neurotransmitter release (Rothman, 1983 (Rothman, , 1984 Rothman and Olney, 1986; Abele et aI., 1990) , we postulate that attenuation of excitatory neuro transmission in the mammalian brain by BAPT A AM may represent a mechanism by which these agents reduce excitotoxic damage to neurons.
Somatic field potentials are attenuated by BAPTA-AM. Electrophysiological recordings were performed in hippocampal brain slices prepared as above (see Materials and Methods). Stimulation of the Schaffer collateral pathway ( Fig. 2A , inset) pro duced a population spike in CAl neurons of about 2-m V amplitude, representing a compound postsyn aptic potential in response to the excitatory stimu lus. Since transmitter release at presynaptic termi nals requires a rise in presynaptic [Ca 2 + Ji, it is ex pected that presynaptic Ca 2 + chelation with BAPTA-AM will attenuate transmitter release and, hence, the amplitude of the postsynaptic potential.
Superfusion of the brain slices with ACSF con taining 50 /-LM BAPTA-AM for 15 min attenuated the population spike (PS) amplitude ( Fig. 2A and  B) , corroborating the hypothesis that excitatory neurotransmission in the slice was decreased. The chelator's effects persisted and frequently in creased for many minutes once BAPTA-AM was removed from the perfusate. This suggests that much of the introduced chelator was trapped in the extracellular matrix, from which its passage into the cells could continue (compare Fig. 2A, 2 and 3). In five experiments, superfusing the slices with BAPTA-AM produced a 73 ± 15.7% depression in the PS amplitude (p < 0.05, Student's t test) when measurements were taken 15 min after the end of the BAPTA application (Fig. 2C) .
The PS that remained after applying BAPT A-AM To control for the effects of OMSO, cyclo dextrin, and neostigmine, the slices were perfused with ACSF containing the same concentrations of the above agents be fore and after the application of BAPTA AM.
Schaffer collateral fiber pathway ,-Record
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o 30 60 90 120 0 (n = 5) 150 could be almost-completely abolished by the induc tion of brief (2-min) hypoxia ( Fig. 2A, 4) , a maneu ver known to cause a total, but apparently fully reversible blockade of excitatory synaptic transmis sion in the CAl region of the hippocampus (Krn jevic and Leblond and Krnjevic, 1989; Zhang and Krnjevic, 1993) . Interestingly, in all five experiments, reversal of anoxia (return to 95% O 2 /5% CO 2 ) partially overcame the depression of the PS amplitude by BAPT A-AM ( Fig. 2A, 5) , causing a transient, self-limiting, "pseudoreversal" of the BAPTA-AM effect lasting 15-20 min. After this time, the PS amplitude returned to the level initially produced by the BAPT A-AM superfusion ( Fig. 2A, 6 ). One explanation for this phenomenon is that the affected neurons contain only a finite number of BAPTA molecules, which can be satu rated by the rise in [Ca 2 +]j occurring during the anoxic period (Mitani et ai. , 1993) . Upon reversal of anoxia, these BAPT A molecules may remain neu tralized by Ca2+ ions for several minutes, as the [Ca 2 +]j remains elevated, making the chelators un available for binding new Ca2+ ions. This would allow subsequent stimulation-evoked Ca2 + influx to trigger normal-sized excitatory responses, account ing for a transient reduction (or apparent reversal) of the chelator's effect on the PS amplitude. The chelator's ineffectiveness is overcome in time with the restoration of cellular energy levels and the sub sequent restoration of physiological [Ca 2 +]j through the extrusion and/or sequestration of Ca2+ ions .
Time (min)
The phenomenon here is similar to previous obser vations that in frog synapses, repetitive stimulation decreases the effectiveness of BAPT A in blocking transmitter release (M. Charlton and R. Robitaille, personal observations).
Excitatory postsynaptic potentials are attenuated by BAPTA-AM. The method of investigating the effect of BAPT A-AM on synaptic transmission us ing field potential measurements is limited, because the measurements may be influenced by factors other than changes in synaptic transmission (includ ing postsynaptic membrane potential, inhibitory transmission, postsynaptic input resistance, and others). Thus, to resolve further the effects of BAPTA-AM on excitatory neurotransmission, we proceeded to make sharp microelectrode recordings in hippocampal CAl neurons stimulated via the Schaffer collateral pathway as in Fig. 2 . Briefly, spike-frequency adaptation (accommodation) and post-spike-train AHPs in CAl neurons are phenom ena known to be governed mainly by a slow Ca2+dependent K + conductance and are attenuated by intracellular Ca2+ chelation (Marty and Neher, 1985; Nicoll, 1988; Schwindt et ai., 1992) . Although these processes may not be related to mechanism governing Ca 2 + -dependent neurotoxicity, reduc tions in AHP size and accommodation indicate physiologically relevant intraneuronal chelator ac cumulations. In a previous report we showed that these parameters were attenuated in animals treated with BAPT A-AM, demonstrating delivery of the compound to the CNS in vivo. Furthermore, this effect was reproduced by direct injections of BAPT A into untreated neurons (Tymianski et al. , 1993b) .
The representative recordings in Fig. 3A and B show that excitatory postsynaptic potential s (EPSPs) were attenuated in neurons from slices su perfused with BAPTA-AM. We interpret the atten uation of the EPSPs and of the PS amplitude (Fig. 2) by BAPTA-AM as representing a presynaptic ef fect. This is because in previous experiments, the direct injection of BAPT A salt (the active ionized chelator) into postsynaptic neurons enhanced, rather than depressed the evoked postsynaptic re sponses (Niesen et al. , 1991) . Hence, the depres sion of field potentials and EPSPs by BAPTA-AM cannot be explained by its known postsynaptic ac tions.
The attenuation in EPSP size was accompanied by reductions in spike-frequency adaptation and in the amplitude of the AHPs (Fig. 3C and D) as re ported previously in neurons treated in vitro (Nie sen et al., 1991) and in vivo (Tymianski et al., 1993b) . The latter finding suggests that considerable Ca 2 + buffering must occur in the immediate sub membrane regions encompassing the Ca 2 +activated potassium channels responsible for the hyperpolarizing response. The observed attenua tions of the EPSP amplitude and AHP size occurred in the absence of any changes in membrane input resistance (Rj; Fig. 3E ), thus ruling out possible ar tifacts from changes in membrane conductances or from instability of the recordings. Overall, AHP and EPSP size were attenuated by about 30% as shown in several experiments ( Fig. 3F and G) . This result, along with our previous observations in dentate granule cells (Niesen et al. , 1991) , strengthens the hypothesis that an important mechanism of Ca2 + chelator action in the mammalian brain is the atten uation of excitatory synaptic transmission. Further more, the effects on the AHP observed here were similar to those obtained in recordings from brain slices removed from animals treated with BAPT A AM in vivo (Tymianski et al., 1993b) . This suggests that the mode of in vitro BAPTA-AM superfusion employed here produces intracellular chelator accumulations comparable to in vivo administra tion.
BAPT A-AM attenuates cortical infarction volumes
h after ischemia induction
Pretreatment of neurons in vitro and in vivo with BAPTA-AM is reported dramatically to attenuate neurodegeneration induced by the neurotoxin glu tamate or by focal cortical ischemia, respectively (Tymianski et al., 1993b ). An important criticism of this finding is that the paradigms used to demon strate the chelators' effectiveness employed rela tively short observation periods. For example, the extent of the cerebral infarction was assayed at only 4 h following MCAO to allow for comprehensive monitoring of physiological parameters throughout the entire experimental period. Unfortunately, this approach did not provide a distinction as to whether the Ca 2 + chelators simply delayed the onset of neu-rode generation or whether treatment with these agents produced a more permanent neuroprotective effect. Therefore, in the present study, we exam ined whether animals treated with BAPTA-AM would still have smaller infarctions when examined 24 h after the onset of focal cerebral ischemia.
Complications and behavioral assessment. A to tal of 30 animals was treated according to the pro tocol in Fig. 4A . There were three mortalities, one in each experimental group: Two were related to cardiorespiratory difficulties resulting from trau matic endotracheal intubation, and one was due to pyloric obstruction. Three other animals, also in each group, were excluded from the trial at the time of surgery due to technical difficulties with MCAO (severe subarachnoid hemorrhage in two, duplicate MCA in one). All animals (treated and controls) suf fered from transient hematuria lasting about 2-3 h. This was a consequence of the administration of intravenous DMSO, because animals treated with saline in a similar fashion did not experience this complication (M. Tymianski and M. C. Wallace, personal observations). Seizures were not observed in any of the rats. Physiological parameters before, during, and 60 min after the induction of focal ce rebral ischemia showed no significant differences among the MK-801, BAPTA-AM, and vehicle groups (Table O . However, there were slight differ ences in the clinical course of the rats in the three groups: Following cessation of anesthesia, rats treated with MK-801 took longer to resume respi ratory efforts and to become extubated compared with controls (Table 2 ) (see Rod and Auer, 1992) . In contrast, animals treated with BAPT A-AM were not adversely affected despite this agent's profound effects on Ca2 + -dependent signaling and on excit atory neurotransmission (Figs. 2 and 3) . The rea sons for the lack of any apparent neurobehavioral effect of BAPTA-AM remain to be elucidated. Neu rologically, animals treated with BAPT A-AM had no apparent deficits at 24 h, whereas some control animals and animals treated with MK-801 were neu rologically impaired when assessed by the neuro logical grading scale of Bederson et al. (1986) 
(Ta ble 2).
Effects of treatment on cortical ischemic dam age. Microscopic neuropathological examination of the rat brains revealed that they were well fixed as evidenced by the good neuronal morphology of nonischemic areas, the absence of intravascular blood, and the lack of cytological artifacts. Isch emic damage was observed only within the territory of the occluded MCA in the dorsolateral neocortex. Values are means ± SD. There were no statistical differences between any of the group means (by ANOV A at the p = 0.05 level of significance). Values at MCAO were measured �IO min or prior to MCAO. BP, blood pressure.
shrinkage and triangulation of the nucleus, astro cytic swelling, and vacuolated neuropil. Rats treated with BAPT A-AM (20 mg/kg) prior to the induction of focal neocortical ischemia sus tained significantly smaller infarction volumes than the untreated controls (Fig. 4B ). On average, treat ment with BAPT A-AM reduced infarction volumes by 50.5% (p = 0.018), a treatment effect consistent with that observed in previous studies in which in farction volumes were assessed 4 h after ischemia induction (Tymianski et aI., 1993b) . The areas of neuronal death in BAPTA-AM-treated animals were reduced at each stereotactic coronal plane ex- Time to extubation was the average time interval (mean ± SD) from cessation of general anesthesia to the moment the rat was able to extubate itself by pulling away from the endotracheal tube. Rats treated with MK-801 (*) took significantly longer to awaken than controls or rats treated with BAPTA-AM (ANOVA; p < 0.001). Neurological grading was per formed as per Bederson et al. (1986) (see Materials and Methods). One animal in the MK·801 group (**) could not be assessed by this grading system due to continued lethargy at 24 h.
J Cereb Blood Flow Metab, Vol. 14. No. 6, 1994 amined, with the most consistent sparing effects (i.e., statistically significant differences) seen in the planes more than 5 mm anterior to the interaural line (Fig. 4C ). In this experimental series, BAPTA AM pretreatment was more effective than MK-801 in reducing infarction volumes as assessed 24 h af ter MCAO. Although animals treated with MK-801 also sustained a modest reduction in infarction vol ume (26%), this sparing effect was not statistically significant 24 h after MCAO (p = 0. 27). Others have also reported no effect of MK-801 (0.5 mg/kg) in the focal ischemia model employed here [e.g., Boxer et al. (1990) on rat focal infarction evaluated at 48 h]. However, there are few published reports on the effectiveness of MK-801 24 h or more after the induction of focal cerebral ischemia in the rat. Therefore, we cannot exclude the possibility that the lack of MK-801 effect at 24 h reflects our sample size, selected because it was adequate for demon strating the MK-801 effect in shorter (4-h) cerebral ischemia paradigms (Park et al. , 1988a) . Also, it is conceivable that the addition of DMSO to the present treatment paradigm produced deleterious effects that could not be overcome by MK-801.
Since the, evaluation of cerebral infarction vol umes was restricted to a 24-h postischemic period, we cannot generalize on the permanence of the ob served neuroprotective effect beyond this time pe riod. However, these findings lessen the possibility that Ca 2 + chelators simply delay the onset of neu rodegeneration, as it is generally thought that in the permanent neocortical ischemia model of Brint et al. (1988) , acute neurodegeneration is complete by 24 h following permanent MCAO [ (Buchan et aI., 1992; Dawson et aI. , 1993) ; also, compare the in farction volumes in the present report and that of Tymianski et aI. (l993b) ].
DISCUSSION
Here we address the possible mechanism and du ration of neuroprotective action of the prototypical cell-permeant Ca2 + chelator BAPT A-AM (Fig. l) . Using electrophysiological techniques in the rat hip pocampal slice, our studies in CAl neurons con firmed that the application of BAPTA-AM reduced Ca 2 + -dependent post-spike-train hyperpolariza tions, indicating Ca 2 + chelation near the internal cell membrane surface (Fig. 3) (Tymianski et al. , 1993b) . Recordings of CAl somatic field potentials revealed an attenuation of the PS amplitude follow ing BAPT A-AM application (Fig. 2) and a reduction in individual excitatory postsynaptic responses (Fig. 3) , indicating a presynaptic inhibition of excit atory synaptic transmitter release. In determining whether Ca2 + chelators reduce the size of cerebral infarction rather than simply delaying its evolution, we studied the effects of BAPTA-AM treatment in a 24-h focal neocortical ischemia paradigm. Cortical infarction volumes in animals treated with BAPT A AM were markedly reduced (Fig. 4) , illustrating a persistence of neuroprotection by the Ca2 + chelator 24 h following permanent MCAO.
Role of cellular Ca 2 + buffering in neuroprotection
The strategy of neuroprotection in vivo by cell permeant Ca2 + chelating agents is a recent devel opment. Hence, few experimental data exist for forming a basis for future experiments and for ra tional drug design. While it is reasonably estab lished that loading neurons with Ca2+ chelators such as quin-2 and BAPTA in vitro decreases their immediate vulnerability to certain insults such as excitotoxin excess and excitatory overstimulation (Scharfman and Schwartzkroin, 1989; Kudo et aI. , 1990) , the mechanism and the duration of this effect are unknown. Using the fluorescent Ca2+ indicator fura-2, we have shown in cultured mammalian neu rons that this phenomenon of enhanced resilience is associated with an attenuation of excitotoxin induced [Ca2+]j increases (Tymianski et aI. , 1993b) . Although these finding are consistent with the intu itive view that lessening excessive neuronal Ca2 + load during cerebral ischemia would result in neu roprotection, sufficient evidence also exists to sug gest that Ca2 + chelators' mechanism of neuropro tection may be considerably more complex.
First, there is conflicting evidence that neurons' Ca2+ buffering capacity actually correlates with in creased cell survival. While some reports suggest that neurons containing high levels of endogenous Ca2+ binding proteins such as calbindin-D28K and parvalbumin are less susceptible to hypoxic or ex citotoxic insults (Scharfman and Schwartzkroin, 1989; Mattson et aI., 1991; Goodman et aI., 1993) , others fail to find such associations (Freund et aI., 1990; Weiss et aI., 1990) . Physiologically, Ca2+ binding proteins may modulate neuronal excitabil ity (Blaustein, 1988; Kohr and Mody, 1991) and may attenuate Ca2+ entry through Ca2+ channels and depolarization-evoked [Ca2 + L transients (Lledo et aI., 1992) . However, the applicability of such findings to the mechanisms governing isch emic neurodegeneration is unclear.
Second, despite numerous studies that support the association between Ca2 + overload and neuro toxicity (e.g., Ellren and Lehmann, 1989; Goldberg et aI., 1989; Manev et aI., 1989) , the mechanisms by which Ca2 + ions trigger toxic events remain poorly defined. Therefore, it is presently impossible to pin-point the process by which Ca2 + chelating agents prevent this toxicity from occurring.
Third, although a protective effect of Ca2+ che lators was shown in experiments in which cell sur vival was gauged within a short time span (many minutes to a few hours) following the neurotoxic insult (Scharfman and Schwartzkroin, 1989; Kudo et aI. , 1990; Tymianski et aI. , 1993b) , some in vitro evidence suggests that excessive exposure to these agents can be detrimental to cells. For example, Dubinsky (1993) found that if cell viability was gauged 24 h following the neurotoxic insult in the presence of permeant Ca2+ buffers, neuronal sus ceptibility to excitotoxins increased. Given the crit ical role of Ca2 + ions as intracellular second mes senger (for reviews see Mayer and Miller, 1990; Miller, 1992) , it is not unexpected that a protracted interruption of physiological Ca2 + signaling could be harmful, rather than beneficial to neurons. How ever, the present study contradicts the findings of in vitro toxicity, as Ca2 + chelator toxicity is not seen when BAPT A-AM is administered in vivo, and neu ronal survival at 24 h is enhanced following focal cerebral ischemia. We interpret this as follows: When neurons are overloaded with Ca2+ buffering agents, their long-term survival may be compro mised as the homeostatic processes required for re covery from a neurotoxic insult may in themselves exhibit calcium dependence. At 24 h following the insult, the discrepancy between the toxicity of BAPT A in vitro and its protective effects in vivo suggests that, in the latter, neurons either fail to accumulate excessive concentrations of the chela tor or are capable of extruding and/or metabolizing these compound more effectively than in vitro.
A hypothesis of the mechanisms of Ca 2 + neurotoxicity and neuroprotection by cell-permeant
Ca 2 + chelators
The controversies above confirm the complexi ties underlying the process of Ca2 + -dependent neu rotoxicity and of the possible effects of exogenously applied BAPTA-based Ca2+ chelators. Presently, there exists a considerable body of literature on Ca2 + -dependent neurotoxicity. Virtually every ma jor known Ca2 + -dependent intracellular process has been implicated as a causative neurotoxic mechanism. For example, neurotoxic actions of Ca2+ overload have been ascribed to the overstim ulation of enzymes such as phospholipases, plas malogenase, cal pains , protein kinases, guanylate cyclase, nitric oxide synthetase, calcineurins, and endonucleases. Presumably, this leads to an over production of toxic reaction products such as free radicals, lethal alterations in cytoskeletal organiza-tion, or the activation of genetic signals leading to cell death (Farooqui and Horrocks, 1991; Tominaga et aI. , 1993) .
According to contemporary views of physiologi cal and pathological cellular calcium homeostasis, the fact that Ca2+ ions are involved in governing such a large number of different cellular processes implies that there must exist, within individual cells, mechanisms for spatial and temporal com partmentalization of different Ca2 + signaling path ways. Substantial evidence now exists to support this assertion. For example, Ca 2 + channels are stra tegically distributed throughout the plasma mem brane so as to maximize Ca 2 + influx in subcellular regions subserving relevant cellular functions (Lip scombe et aI., 1988; Robitaille et aI. , 1990 Robitaille et aI. , , 1993 Westenbroek et aI., 1990; Llinas et aI. , 1992; Gola and Crest, 1993) . In the case of glutamate receptors, it is shown that N-methyl-D-aspartate (NMDA) re ceptors are clustered throughout neurons on syn apses (Jones and Baughman, 1991) , dendritic spines (Connor et aI., 1988; Muller and Connor, 1991) , and neuronal somata (Jones et aI. , 1990; Benke et aI., 1993) . Subcellular Ca2+ transients can have differ ent temporal profiles in different cellular compart ments, accounting for the formation of intracellular [Ca 2 +]i gradients (Guthrie et aI. , 1993; Muller and Connor, 1991; Lechleiter and Clapham, 1992) . Such findings indicate that Ca2 + signaling in cells can trigger distinct processes by colocalizing their effec tor mechanisms with Ca2 + entry points responsible for the formation of Ca2+ microdomains (e.g., Gola and Crest, 1993; Lerea and McNamara, 1993; Ro bitaille et aI., 1993) .
This view implies that Ca 2 + -triggered neurotox icity may not necessitate a "global" rise in [Ca2+]i but, rather, can be caused by a subcellular rise in Ca 2 + concentration at strategic submembrane loca tions. In support of this we have recently shown that in cultured spinal neurons, Ca2+ neurotoxicity was highly dependent on the source of Ca 2 + influx, so that early neurodegeneration was preferentially triggered by Ca 2 + influx through NMDA receptor channels, although other glutamate receptors were capable of producing equal (but nontoxic) [Ca2+]i increases (Tymianski et aI. , 1993a) . For this situa tion to exist, NMDA receptors may be colocalized with rate-limiting enzymes or substrates specifically required in processes that can cause rapid neurode generation. Thus, Ca2+ influx through NMDA channels preferentially activates these processes.
The notion that early neurotoxicity may require a very localized diffusion of Ca 2 + ions from their in flux sites to nearby sites of action underlies the ra tionale for selecting BAPT A as a means to interrupt J Cereb Blood Flow Metab, Vol. 14, No.6, 1994 this process. BAPT A is highly Ca2 + specific, and has rapid Ca 2 + -binding kinetics compared with its parent compound, EGTA (Tsien, 1980; Neher, 1986) . In addition, the mobility of Ca2+ chelators in cytoplasm is high (Strautman et aI., 1990; Adler et aI., 1991) , allowing for effective Ca 2 + buffering in microdomains encompassing potential sites of neu rotoxic Ca2+ influx (Neher, 1986; Stern, 1992) and the redistribution of potentially harmful submem brane Ca 2+ gradients (Speksnijder et aI., 1989) .
The above hypothesis is highly consistent with our present demonstration of the attenuation of ex citatory neurotransmission in hippocampal slices by BAPTA (Figs. 2 and 3) . Experiments in a number of preparations have established that synaptic trans mitter release requires sharply localized elevations of lCa2+t located in submembrane domains near the active zones of synaptic terminals (for reviews, see Smith and Augustine, 1988; Augustine et aI., 1991) . Highly diffusible Ca 2 + buffers such as BAPTA and dimethyl-BAPTA can markedly atten uate neurotransmitter release in squid and frog syn aptic terminals (Adler et aI. , 1991; Robitaille and Chariton, 1992; Robitaille et aI., 1993) , presumably by shuttling Ca2 + ions away from synaptic active zones where transmitter release is triggered. This "Ca2+ shuttling" process is distinct from the hy pothesis that Ca2 + chelators simply act as addi tional calcium "sinks"-enhancing bulk cytoplas mic Ca2 + buffering capacity. According to this mechanism, the highly diffusible BAPT A molecules may operate as facilitators of Ca2 + diffusion by che lating Ca2+ ions near their source of influx, where they are present at high concentrations, and releas ing them at sites remote from their location of phys iological action [see Speksnijder et aI. (1989) for the "facilitated diffusion" theory]. A single BAPT A molecule may be repeatedly involved in the Ca 2 + shuttling process, thus requiring chelator concen trations lower than those needed to enhance bulk Ca2+ buffering capacity. The present demonstra tion of an attenuation in excitatory neurotransmis sion suggests that, as in nonmammalian prepara tions, such mechanisms may be operative in excit atory pathways in the hippocampal slice. Since excitotoxin excess is thought to play a key role in triggering neurodegeneration during focal cerebral ischemia (Rothman and Olney, 1986; Choi, 1990; Siesjo, 1992a,b) , attenuation of excitatory neuro transmission may reduce neuronal damage (Graham et aI., 1993; Matsumoto et aI., 1993) . The above hypothesis suggests a likely mechanism by which this process occurs.
Since the microdomain hypothesis of Ca 2 + neu rotoxicity is unproven in vivo, other mechanisms of Ca2 + chelator action must be considered. These may include a direct pharmacological effect of the chelator or its by-product on an as yet undiscovered receptor. Alternately, despite the selectivity of BAPT A for Ca2 + , its effects might stem from che lation of other ions such as zinc, which is also bound with a high affinity (Csermely et aI., 1989) . For example, zinc can increase the activity of pro tein kinase C (Csermely et aI. , 1988; Baba et aI. , 1991) , which may act as a mediator of excitotoxicl ischemic cell damage (Zivin et aI., 1990) . Finally, it is impossible in an in vivo system to rule out com pletely all indirect, systemic effects of a drug. For example, since BAPT A analogues can be delivered into cell types other than neurons (N egulescu et aI. , 1989; Speksnijder et aI., 1989; Van Der Zee et aI., 1989; Williams and Fay, 1990; Lledo et aI., 1992) , it is conceivable that systemic BAPTA-AM adminis tration has extracerebral effects. This could pro duce alterations in factors that are not routinely measured in conventional cerebral ischemia exper iments but that may have consequences on infarc tion size. These may include alterations in extracel lular ionic composition (e.g., rise in Mg2 + ions), changes in glucose energy metabolism, and changes in the phosphorylation state of numerous cell mem brane receptors. While the present experiments controlled for a number of physiological parameters (Table 1) , these measurements may still be inade quate to reflect local hemodynamic changes in in dividual vascular beds or changes in brain temper ature regulation in individual brain areas.
Conclusions
Cell-permeant Ca2 + chelators constitute a unique pharmacotherapeutic approach to cerebral ischemia that protects neurons for at least 24 h following per manent focal neocortical ischemia. While these agents may provide the cells with increased Ca2+ buffering capacity, we have demonstrated that their action may also stem from their ability to attenuate synaptic transmission. However, numerous issues remain unresolved : Particularly, the absence of knowledge on the pharmacokinetics of these agents currently precludes the design of a rational study to test the chelators' effects in a postischemia treat ment paradigm. This serious limitation requires that experiments in the immediate future concentrate on determining the chelators' kinetics, metabolism, and potential toxicity. Posttreatment paradigms may require the development of alternative drug ve hicles and, possibly, improvements on present dos ing regimens.
